June 5 is National HIV/AIDS Long-Term Survivors Awareness Day

The first National HIV/AIDS Long-Term Survivor Awareness Day (NHALTSAD) will take place this week on June 5. The day is one that has historical significance in San Francisco, but also globally, because it was the same day in 1981 that the U.S. Centers for Disease Control (CDC) reported the first cases of a new and devastating disease we now know as AIDS.


AAHIVM, AGS, and ACRIA Release Updated Recommendations for Older Patients with HIV

The American Academy of HIV Medicine (AAHIVM), ACRIA, and the American Geriatrics Society (AGS) this week announced a major update to its 2011 report,  Recommended Treatment Strategies for Clinicians Managing Older Patients with HIV, available online at Revised topics include assessing functional capacity, smoking cessation, and management of diabetes, COPD, osteoporosis, and hypertension.


ASCO: HCV Reactivation, Brain Involvement Do Not Worsen Lymphoma Survival for People with HIV

Reactivation of hepatitis C was common among HIV positive people with lymphoma, but did not appear to lead to worse outcomes or decreased survival, according to a study presented at the 50th American Society of Clinical Oncology (ASCO) meeting this week in Chicago. A related study found that having central nervous system involvement at the time of diagnosis did not decrease survival of people with AIDS-related lymphoma.


New Studies Offer More Insight on HIV Sexual Transmission and Prevention

A new estimate puts the likelihood of HIV transmission via receptive anal sex at 138 per 10,000 acts, but looking at probabilities over a longer period provides a better understanding of risk than per-act probabilities, according to a pair of studies in the May 6 advance online edition of AIDS. Mathematical models showed that combining prevention methods -- especially those that include antiretroviral treatment-as-prevention or PrEP -- can greatly reduce the risk of transmission.


HIV and Hepatitis C Highlights from CROI 2014

Latest Positive Pulse Newsletter

In this overview, Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins School of Medicine discuss selected highlights from the recent Conference on Retroviruses and Opportunistic Infections (CROI 2014), focusing on antiretroviral therapy, HIV cure research, and new treatments for hepatitis C and HIV/HCV coinfection.


Kidney Drug Sevelamer May Reduce Gut Leakage During Acute HIV Infection

The phosphate-binding agent sevelamer can bind to bacterial toxins and reduce excessive immune activation in macaque monkeys with a simian virus similar to HIV, according to a report in the June 2 Journal of Clinical Investigation. A related study, however, failed to see a reduction in inflammation biomarkers in people with untreated HIV disease.


Rilpivirine Is Associated with Less Blood Fat Elevation than Efavirenz

People with HIV who started first-line treatment with a regimen containing rilpivirine (Edurant, also in the Complera coformulation) had smaller blood lipid increases and were less likely to have abnormal levels than those who started on efavirenz (Sustiva, also in the Atripla coformulation), according to 2-year data from the ECHO and THRIVE trials published in the April 11 online edition of Clinical Infectious Diseases.